Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia

Front Immunol. 2023 Dec 12:14:1296501. doi: 10.3389/fimmu.2023.1296501. eCollection 2023.

Abstract

Background: Immune control of Mycobacterium tuberculosis (Mtb) infection is largely influenced by the extensive disease heterogeneity that is typical for tuberculosis (TB). In this study, the peripheral inflammatory immune profile of different sub-groups of pulmonary TB patients was explored based on clinical disease severity, anemia of chronic disease, or the radiological extent of lung disease.

Methods: Plasma samples were obtained from n=107 patients with active pulmonary TB at the time of diagnosis and after start of standard chemotherapy. A composite clinical TB symptoms score, blood hemoglobin status and chest X-ray imaging were used to sub-group TB patients into 1.) mild and moderate-severe clinical TB, 2.) anemic and non-anemic TB, or 3.) limited and extensive lung involvement. Plasma levels of biomarkers associated with inflammation pathways were assessed using a Bio-Plex Magpix 37-multiplex assay. In parallel, Th1/Th2 cytokines were quantified with a 27-multiplex in matched plasma and cell culture supernatants from whole blood stimulated with M. tuberculosis-antigens using the QuantiFERON-TB Gold assay.

Results: Clinical TB disease severity correlated with low blood hemoglobin levels and anemia but not with radiological findings in this study cohort. Multiplex protein analyses revealed that distinct clusters of inflammation markers and cytokines separated the different TB disease sub-groups with variable efficacy. Several top-ranked markers overlapped, while other markers were unique with regards to their importance to differentiate the TB disease severity groups. A distinct immune response profile defined by elevated levels of BAFF, LIGHT, sTNF-R1 and 2, IP-10, osteopontin, chitinase-3-like protein 1, and IFNα2 and IL-8, were most effective in separating TB patients with different clinical disease severity and were also promising candidates for treatment monitoring. TB patients with mild disease displayed immune polarization towards mixed Th1/Th2 responses, while pro-inflammatory and B cell stimulating cytokines as well as immunomodulatory mediators predominated in moderate-severe TB disease and anemia of TB.

Conclusions: Our data demonstrated that clinical disease severity in TB is associated with anemia and distinct inflammatory immune profiles. These results contribute to the understanding of immunopathology in pulmonary TB and define top-ranked inflammatory mediators as biomarkers of disease severity and treatment prognosis.

Keywords: anemia; chemokines; clinical symptoms; cytokines; disease severity; inflammation; lung involvement; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia*
  • Biomarkers
  • Cytokines
  • Hemoglobins
  • Humans
  • Inflammation
  • Patient Acuity
  • Tuberculosis*
  • Tuberculosis, Pulmonary*

Substances

  • Cytokines
  • Biomarkers
  • Hemoglobins

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This project was funded by grants from the Swedish Heart and Lung Foundation (Hjärt-Lungfonden, HLF) (2019-0299/2019-0302 and 2022-0484 to SB) and the Swedish Research Council (Vetenskapsrådet, VR) (2019-01744/2022-00970 and 2019-04720/2022-03174 to SB). KID funding for doctoral student ML was provided by Karolinska Institutet. SB has ongoing research grants from HLF and VR (2023–2025). The APC was funded by VR.